CASE COMMENTS : MERGER - MARKET DEFINITION - HUMAN HEALTH

Phase I clearance: The European Commission confirms prior approach to market definition for human health pharmaceuticals (Merck/Schering Plough)

KEYWORDS

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. – Eur. Comm, 22 October 2009, Merck/Schering Plough, case COMP/M.5502 On October 22, 2009, the European Commission approved the acquisition of the US pharmaceutical company Schering-Plough by Merck, another US pharmaceutical company. This decision

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

This document is protected by copyright laws and international copyright treaties. Non-authorised use of this document constitutes a violation of the publisher's rights and may be punished by up to 3 years imprisonment and up to a € 300 000 fine (Art. L 335-2 Code de la Propriété Intellectuelle). Personal use of this document is authorised within the limits of Art. L 122-5 CPI and DRM protection.

PDF Version

Author

  • Van Bael & Bellis (Brussels)
    Belgium 23 contributions 23804 visits

Quotation

David Hull, Phase I clearance: The European Commission confirms prior approach to market definition for human health pharmaceuticals (Merck/Schering Plough), 22 October 2009, Concurrences N° 3-2010, Art. N° 31941, pp. 127-128

Visites 1551

All reviews